Alunbrig (brigatinib) vs Krazati (adagrasib)
Alunbrig (brigatinib) vs Krazati (adagrasib)
Alunbrig (brigatinib) and Krazati (adagrasib) are both targeted therapies used in the treatment of non-small cell lung cancer (NSCLC) with specific genetic mutations. Alunbrig is specifically indicated for NSCLC patients with anaplastic lymphoma kinase (ALK) positive mutations and has been shown to be effective after initial therapy with another ALK inhibitor has failed. In contrast, Krazati is designed to target NSCLC with KRAS G12C mutations, representing a different subset of genetic alterations within lung cancers, and is used in patients who have received at least one prior systemic therapy. Patients should consult with their oncologist to determine which medication is appropriate based on the specific genetic profile of their cancer and their previous treatments.
Difference between Alunbrig and Krazati
| Metric | Alunbrig (brigatinib) | Krazati (adagrasib) |
|---|---|---|
| Generic name | Brigatinib | Adagrasib |
| Indications | Non-small cell lung cancer (NSCLC) with ALK mutations | Non-small cell lung cancer (NSCLC) with KRAS G12C mutation |
| Mechanism of action | ALK and EGFR inhibitor | KRAS G12C inhibitor |
| Brand names | Alunbrig | Krazati |
| Administrative route | Oral | Oral |
| Side effects | Nausea, diarrhea, fatigue, cough, headache | Diarrhea, nausea, vomiting, fatigue, increased liver enzymes |
| Contraindications | None known | None known |
| Drug class | Tyrosine kinase inhibitor | Small molecule kinase inhibitor |
| Manufacturer | Takeda Oncology | Mirati Therapeutics |
Efficacy
Alunbrig (brigatinib) Efficacy in Lung Cancer
Alunbrig (brigatinib) is an anaplastic lymphoma kinase (ALK) inhibitor used in the treatment of non-small cell lung cancer (NSCLC) with a specific genetic marker, an ALK mutation. The efficacy of Alunbrig for the treatment of ALK-positive metastatic NSCLC was primarily shown in clinical trials that evaluated response rate and duration of response. In a pivotal trial, patients treated with brigatinib after crizotinib failure showed a high objective response rate (ORR), with many experiencing a significant shrinkage in tumor size. Additionally, brigatinib demonstrated a noteworthy intracranial response in patients with brain metastases, a common complication of advanced NSCLC.
The progression-free survival (PFS) rates with Alunbrig have also been encouraging. In the same trial, brigatinib significantly extended the PFS compared to chemotherapy, indicating its potency in delaying disease progression. The overall survival data also suggested a potential benefit, although long-term results are still being evaluated. The efficacy of Alunbrig has led to its approval for first-line treatment of ALK-positive NSCLC in many regions, providing an important option for patients with this specific type of lung cancer.
Krazati (adagrasib) Efficacy in Lung Cancer
Krazati (adagrasib) is a newer medication designed to target KRAS G12C-mutated NSCLC. KRAS mutations are among the most common genetic abnormalities in NSCLC, and the G12C mutation represents a subset of these mutations. Adagrasib has shown promise in early clinical trials, demonstrating an ability to inhibit tumor growth in patients with KRAS G12C-mutated NSCLC who have been previously treated with chemotherapy and/or other targeted therapies.
In clinical studies, adagrasib has shown an ORR that is notable for this challenging to treat population. The durability of responses and disease control rates have been particularly encouraging, with many patients experiencing a stabilization of their disease. While the data on overall survival and PFS are still maturing, the initial findings suggest that Krazati may offer a meaningful clinical benefit in a patient population with historically limited treatment options. As research continues, Krazati may become a standard component of care for patients with KRAS G12C-mutated NSCLC.
Regulatory Agency Approvals
Alunbrig
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Krazati
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Access Alunbrig or Krazati today
If Alunbrig or Krazati are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us